Biogen tops quarterly profit estimates, eyes deals to build early-stage pipeline (updated)
Biogen trims annual profit forecast on expected hit from R&D-related charges
Merck, Eisai discontinue late-stage study for liver cancer therapy
Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion (updated)
Merck-Eisai's kidney cancer drug combo meets one main goal in late-stage study (updated)
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
Brief: Merck And Eisai Announce WELIREG Plus LENVIMA Met Primary Endpoint Of Progression-Free Survival In Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Brief: Eisai And Biogen Announce U.S. Availability Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection Maintenance Dose For Treatment Of Early Alzheimer’S Disease
Brief: Eisai And Biogen Announce U.S. Availability Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection Maintenance Dose For Treatment Of Early Alzheimer’S Disease
Crystalys Therapeutics launches with $205 million funding round for trials of gout drug
Factbox: Asian and European drugmakers' branded drugs imported to the US market
Notice Of Settlement Of Patent Infringement Litigation Related To Lenvatinib In U.S.
Brief: SEED Therapeutics Completes $30 Million Series A-3 Financing
Brief: BioArctic Says Rolling sBLA Initiated To The U.S. FDA For Leqembi As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Disease Under Fast Track Status
Approves Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection For Maintenance Dosing For Treatment Of Early Alzheimer's Disease
Brief: FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Allarity Therapeutics jumps on US FDA's 'fast track' tag for ovarian cancer therapy
Table: Eisai -Q1 group results (IFRS)